| Identification | Back Directory | [Name]
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide | [CAS]
306959-01-3 | [Synonyms]
MYLS22
N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-3-methyl-1-phenylthieno[2,3-c]pyrazole-5-carboxamide
1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-3-methyl-1-phenyl- | [Molecular Formula]
C24H21N5O2S | [MDL Number]
MFCD01062681 | [MOL File]
306959-01-3.mol | [Molecular Weight]
443.52 |
| Hazard Information | Back Directory | [Biological Activity]
MYLS22 is a first-in-class, selective optic atrophy 1 (OPA1) inhibitor. It can target endothelial cell OPA1 to reduce tumor growth and inhibit angiogenesis by affecting NFkB activity and angiogenic gene expression. | [in vivo]
MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice. | Animal Model: | 6-week-old C57BL6/J mice with B16F10 melanomas | | Dosage: | 10 mg/kg/die | | Administration: | Peritumoral injection; every 2 days for 14 days | | Result: | Caused the tumor growth curtailed. | | [target]
|
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|